Intrathecal Dexmedetomidine Versus Intrathecal Morphine Inpatients Undergoing Cardiac Valve Replacement Surgeries
Cardiac Valve Disease
About this trial
This is an interventional supportive care trial for Cardiac Valve Disease
Eligibility Criteria
Inclusion Criteria: - Cardiac patient scheduled for elective open heart valve replacement surgery. Exclusion Criteria: • Patient refusal Coagulation disorders History of known allergy to the used drugs. Combined procedures (e.gif combined with coronary artery bypass or aortic root surgeries). If thoracotomy or min-sternotomy is planned for the surgery. Re-do and emergency surgeries. History of chronic chest diseases (COPD or IPF). History of thoracotomy, pneumothorax, pneumomediastinum, phrenic nerve injury (as evident by the presence of paralysis of the ipsilateral hemidiaphragm when examined preoperatively). Neuromuscular diseases. Brain injuries.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Intrathecal morphine group (Group M):
Intrathecal dexmedetomidine group (Group D):
• Patients in this group will receive intrathecal morphine (0.5 mg diluted in I ml of normal saline) prior to induction of general anesthesia.
• Patients in this group will receive intrathecal dexmedetomidine (5 mcg diluted in 1 ml of normal saline) prior to induction of general anesthesia.